AQUILUS PHARMACEUTICALS INC — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): Aquilus Pharmaceuticals, Inc. proposes to evaluate th
AQUILUS PHARMACEUTICALS INC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $261,982
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA13-088
- NAICS
- —
- Place of performance
- MA
- Period
- —
Description
DESCRIPTION (provided by applicant): Aquilus Pharmaceuticals, Inc. proposes to evaluate the effects of a proprietary matrix metalloproteinase (MMP) inhibitor, AQU-010, for blocking neuropathic pain and morphine tolerance in a thermal injury (TI) rat model.The goals for Phase I are to scale-up the synthesis of AQU-010, determine its oral pharmacokinetics (PK) and target tissue penetration and then determine its efficacy in the TI-rat model of mechanical and thermal allodynia. A follow-up biomarker and gelatin zymography analysis will be performed to determine if any behavior changes observed from the animal model correspond to changes in metalloproteinase and/or cytokine levels. The ultimate goal of the proposed work is to evaluate whether a matrix metalloproteinase inhibitor can be used to treat pain and/or morphine tolerance in patients suffering from burn injuries without producing euphoria and addiction. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: An estimated 1.25 million individuals